Product Information
TOSYMRA 10 MG NASAL SPRAY is a brand product labeled by Upsher-Smith Laboratories LLC, priced at $108.2212 per EA under NDC 00245081261. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jan 25, 2019.
The High Outlier badge above means this manufacturer's average price in the sumatriptan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
10 mg/.1mL
Manufacturer
Upsher-Smith Laboratories LLCNDC
00245081261
Classification
Brand
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTANApproval Type
New Drug (NDA)
FDA Application
NDA210884FDA Approved
1/25/2019
On Market Since
7/8/2019
Pharmacological Classes
Price Statistics
The NADAC for TOSYMRA 10 MG NASAL SPRAY has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 6.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $108.2212 per EA |
|---|---|
| All-time high | $108.7802 (Mar 12, 2025) |
| All-time low | $101.6129 (Apr 17, 2024) |
| 52-week high | $108.3932 |
| 52-week low | $107.6342 |
| Median price | $108.1796 |
| Average price | $107.6732 |
| Largest weekly change | +6.4% (Jul 10, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the sumatriptan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Upsher-Smith Laboratories LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOSYMRA 10 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for TOSYMRA 10 MG NASAL SPRAY, manufactured by Upsher-Smith Laboratories LLC, is $108.2212 per EA (NDC 00245081261), effective Sep 30, 2026.
How has the price of TOSYMRA 10 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for TOSYMRA 10 MG NASAL SPRAY has risen 6.5%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for TOSYMRA 10 MG NASAL SPRAY?
Since Apr 17, 2024, the NADAC for TOSYMRA 10 MG NASAL SPRAY has ranged from a low of $101.6129 (Apr 17, 2024) to a high of $108.7802 (Mar 12, 2025), with a median of $108.1796 per EA.
Are there cheaper alternatives to TOSYMRA 10 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of TOSYMRA 10 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TOSYMRA 10 MG NASAL SPRAY?
TOSYMRA 10 MG NASAL SPRAY (NDC 00245081261) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a brand product.